Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-01-16
2007-01-16
Nickol, Gary B. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S138100, C424S179100
Reexamination Certificate
active
09929546
ABSTRACT:
The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.
REFERENCES:
patent: 4454106 (1984-06-01), Gansow et al.
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4814275 (1989-03-01), Durda et al.
patent: 4855353 (1989-08-01), Kurami et al.
patent: 4863851 (1989-09-01), McEwan et al.
patent: 4863854 (1989-09-01), Mattes et al.
patent: 4885363 (1989-12-01), Tweedle et al.
patent: 5013645 (1991-05-01), Kim
patent: 5053503 (1991-10-01), Dean et al.
patent: 5057302 (1991-10-01), Johnson et al.
patent: 5118611 (1992-06-01), Smith et al.
patent: 5130118 (1992-07-01), Johnson et al.
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5198208 (1993-03-01), Berg et al.
patent: 5208324 (1993-05-01), Klaveness et al.
patent: 5217704 (1993-06-01), Johnson et al.
patent: 5227471 (1993-07-01), Wright, Jr.
patent: 5229289 (1993-07-01), Kjeldsen et al.
patent: 5314996 (1994-05-01), Wright, Jr.
patent: 5342924 (1994-08-01), Chang
patent: 5419893 (1995-05-01), Berg et al.
patent: 5474756 (1995-12-01), Tweedle et al.
patent: 5489525 (1996-02-01), Pastan
patent: 5531978 (1996-07-01), Berg et al.
patent: 5538866 (1996-07-01), Israeli et al.
patent: 5565562 (1996-10-01), Parker et al.
patent: 5578484 (1996-11-01), Horoszewicz
patent: 5599677 (1997-02-01), Dowell et al.
patent: 5639879 (1997-06-01), Mease et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5674470 (1997-10-01), Tweedle et al.
patent: 5697902 (1997-12-01), Goldenberg
patent: 5763202 (1998-06-01), Horoszewicz
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5804602 (1998-09-01), Slusher et al.
patent: 5846519 (1998-12-01), Tweedle et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5935818 (1999-08-01), Israeli et al.
patent: 5958474 (1999-09-01), Lee et al.
patent: 5965132 (1999-10-01), Thorpe et al.
patent: 6004554 (1999-12-01), Thorpe et al.
patent: 6004555 (1999-12-01), Thorpe et al.
patent: 6022524 (2000-02-01), Maisano et al.
patent: 6036955 (2000-03-01), Thorpe et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6093399 (2000-07-01), Thorpe et al.
patent: 6136311 (2000-10-01), Bander
patent: 6143274 (2000-11-01), Tweedle et al.
patent: 6150508 (2000-11-01), Murphy et al.
patent: 6261535 (2001-07-01), Thorpe et al.
patent: 6331175 (2001-12-01), Goldenberg
patent: 0 208 531 (1987-01-01), None
patent: 0 232 751 (1987-08-01), None
patent: 0 233 619 (1987-08-01), None
patent: 0 279 397 (1988-08-01), None
patent: 0 292 689 (1988-11-01), None
patent: 0 299 795 (1989-01-01), None
patent: 0 315 188 (1989-05-01), None
patent: 0 382 583 (1990-08-01), None
patent: 0 392 423 (1990-10-01), None
patent: 0 466 200 AW (1992-01-01), None
patent: 0 495 878 (1992-07-01), None
patent: 0 594 739 (1994-05-01), None
patent: 0 882 454 AZ (1998-12-01), None
patent: WO 86/06384 (1986-11-01), None
patent: WO 88/02635 (1988-04-01), None
patent: WO 89/00557 (1989-01-01), None
patent: WO 89/06979 (1989-08-01), None
patent: WO 91/15466 (1991-10-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 93/19668 (1993-10-01), None
patent: WO 94/04702 (1994-03-01), None
patent: WO 94/09820 (1994-05-01), None
patent: WO 94/26297 (1994-11-01), None
patent: WO 95/26206 (1995-10-01), None
patent: WO 95/31444 (1995-11-01), None
patent: WO 96/26272 (1996-08-01), None
patent: WO 96/39185 (1996-12-01), None
patent: WO 96/40245 (1996-12-01), None
patent: WO 97/32862 (1997-09-01), None
patent: WO 97/35616 (1997-10-01), None
patent: WO 99/43710 (1999-09-01), None
patent: WO 00/50457 (2000-08-01), None
patent: WO 00/52473 (2000-09-01), None
patent: WO 00/74729 (2000-12-01), None
Jain (Scientific American Jul. 1994).
Weiner (Seminars Oncology, vol. 26, No. 4, 1999, pp. 41-50).
Chang et al., “Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature,”Cancer Res., 59:3192-3198 (1999).
Coleman et al., “Fundamental Immunology,” Wm. C. Brown Publishers, p. 76.
Harlow et al., “Antibodies: A laboratory manual”, Cold Spring Harbor Laboratory, pp. 139-243.
Heston, “Characterization and Glutamyl Preferring Carboxypeptidase Function of Prostate Specific Membrane Antigen: A Novel Folate Hydrolase” (Urology49 (Supp. 3A): 104-112; 106 (1997).
Horoszewicz et al. “Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients,”Anticancer Research, 7:927-936 (1987).
Israeli et al., “Expression of the Prostate-Specific Membrane Antigen”,Cancer Research, 54:1807-1811 (1994).
Israeli et al., “Molecular Cloning of a Complementary DNA Encoding a Prostate-Specific Membrane Antigen”,Cancer Research, 53:227-230 (1993).
Jain, R.K. “Vascular and interstitial barriers to delivery of therapeutic agents in tumors” Cancer and Metastasis Reviews, vol. 9, p. 253-266.
Liu, et al., “Constitutive and Antibody-Induced Internalization of Prostate-Specific Membrane Antigen,”Cancer Res. 58:4055-60 (1998).
Liu, et al., “Monoclonal Antibodies to the Extracellular Domain of Prostate-specific Membrane Antigen also React with Tumor Vascular Endothelium,”Cancer Res. 57:3629-34 (1997).
Murphy et al., “Measurement of Prostate-Specific Membrane Antigen in the Serum With a New Antibody,”The Prostate, 28:266-271 (1996).
Rochon et al., “Western Blot Assay for Prostate-Specific Membrane Antigen in Serum of Prostate Cancer Patients,”The Prostate, 25:219-223 (1994).
Schlom, “Monoclonal antibodies: They're more and less than you think”, in Molecular Foundations of Oncology, ed. by Broder, William & Wilkins.
Silver et al., “Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues,”Clin. Cancer Res. 3:81-85 (1997).
Troyer et al., “Biochemical Characterization and Mapping of the 7EII-C5.3 Epitope of the Prostate-Specific Membrane Antigen,”Urol Oncol., 1:29-37 (1995).
Troyer et al., “Detection and Characterization of the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids,”Int. J. Cancer, 62:552-558 (1995).
Troyer et al., “Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line,”Prostate, 30:232-242. (1997).
Wright et al., “Expression of Prostate-Specific Membrane Antigen in Normal, Benign, and Malignant Prostate Tissues,”Urol. Oncol., 1:18-28 (1995).
Yang et al., AACR Abstract #2996 (1998); “Alpha particle emitter therapy of micrometastases:213Bi-J5 . . . (anti-PSMA) treatment of LnCaP spheroids,” Proceedings of the American Association for Cancer Research, 39:440 (1998).
Dillman R.O et al., “Human Anti-Mouse Antibody Response in Cancer Patients Following Single Low-Dose Injections of Radiolabeled Murine Monoclonal Antibodies” Cancer Biotherapy, 9(1):17-28 (1994).
Dillmann et al., “Toxicities associated with monoclonal antib
Cornell Research Foundation Inc.
Nickol Gary B.
LandOfFree
Treatment and diagnosis of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and diagnosis of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and diagnosis of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3774231